- Anna Torrent: Advisory Board fees from Amgen, Incyte. Honoraria from Kite/Gilead, Incyte, Pfizer, Amgen, Servier, and SERB. Gloria Iacoboni: Consultancy and Honoraria from Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Janssen, Sandoz, Miltenyi, and AstraZeneca. Alejandro Martin García-Sancho: Honoraria and/or consulting fees: Abbvie, AstraZeneca, BeiGene, BMS, Genmab, Gilead/Kite, GSK, Ideogen, Incyte, Janssen, Kyowa Kirin, Lilly, Miltenyi, Regeneron, Roche, Sobi, Takeda. Research support: Gilead/Kite. Cecilia Carpio: Consultancy/Advisory from Regeneron, BMS, Takeda. Honoraria from Takeda, Janssen, and Novartis. Consultancy from Novotech. Pere Barba: Advisory Board and consultancy from Allogene, Amgen, Autolus, BMS/Celgene, Kite/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer and Pierre Fabre. For the remaining authors, no relevant conflicts of interest were declared.